news

ASCEND study to evaluate the effectiveness of TYSABRI® (natalizumab) as a treatment for SPMS

0
SHARES

Posted: 26 January 2012 | | No comments yet

Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS…

Biogen Idec logo

Related organisations

,

Related people